Education
About Us
Working with TipRanks
Follow Us
Artelo Biosciences (ARTL)
:ARTL
ARTL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.92 - $28.60
Previous CloseN/A
Volume8.82K
Average Volume (3M)439.82K
Market Cap
$7.11M
Enterprise Value$6.43M
Total Cash (Recent Filing)$2.07M
Total Debt (Recent Filing)$896.00K
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Nov 18, 2025EPS Estimate
-4.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.61
Shares Outstanding704,425
10 Day Avg. Volume184,171
30 Day Avg. Volume439,820
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$20.00Price Target Upside98.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical MilestonesArtelo's pipeline candidates are slated to reach important clinical milestones, which are underappreciated.
Investigational DrugART27.13 is emerging as a high-value investigational drug, as no therapies have proven to be safe treatments and approved for cancer-related cachexia.
Bears Say
Investment RisksInvestment thesis risks include failure of clinical trials to prove efficacy and potential need to raise additional funds.
Artelo Biosciences News
ARTL FAQ
What was Artelo Biosciences’s price range in the past 12 months?
Artelo Biosciences lowest stock price was $4.92 and its highest was $28.60 in the past 12 months.
What is Artelo Biosciences’s market cap?
Artelo Biosciences’s market cap is $7.11M.
When is Artelo Biosciences’s upcoming earnings report date?
Artelo Biosciences’s upcoming earnings report date is Nov 18, 2025 which is in 94 days.
How were Artelo Biosciences’s earnings last quarter?
Artelo Biosciences released its earnings results on Aug 13, 2025. The company reported -$5.61 earnings per share for the quarter, beating the consensus estimate of -$25.14 by $19.53.
Is Artelo Biosciences overvalued?
According to Wall Street analysts Artelo Biosciences’s price is currently Undervalued.
Does Artelo Biosciences pay dividends?
Artelo Biosciences does not currently pay dividends.
What is Artelo Biosciences’s EPS estimate?
Artelo Biosciences’s EPS estimate is -4.56.
How many shares outstanding does Artelo Biosciences have?
Artelo Biosciences has 704,425 shares outstanding.
What happened to Artelo Biosciences’s price movement after its last earnings report?
Artelo Biosciences reported an EPS of -$5.61 in its last earnings report, beating expectations of -$25.14. Following the earnings report the stock price went up 4.218%.
Which hedge fund is a major shareholder of Artelo Biosciences?
Currently, no hedge funds are holding shares in ARTL
Company Description
Artelo Biosciences
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
ARTL Stock 12 Month Forecast
Average Price Target
$20.00
▲(98.22% Upside)
Technical Analysis
Lineage Therap
―
Soleno Therapeutics
―
Corbus Pharmaceuticals
―
Edesa Biotech
―
Bioxcel Therapeutics
―
Ownership Overview
46.81%
Insiders
2.36% Mutual Funds
<0.01% Other Institutional Investors
50.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---